Literature DB >> 18193839

Dendrimer-epidermal growth factor conjugate displays superagonist activity.

Thommey P Thomas1, Rameshwer Shukla, Alina Kotlyar, Bradley Liang, Jing Yong Ye, Theodore B Norris, James R Baker.   

Abstract

Binding of ligands on to epidermal growth factor receptor (EGFR) can stimulate cell growth; therefore, any application employing EGF as a targeting ligand for a "drug carrier" must evaluate the effect of the conjugate on cell growth. We report the synthesis and in vitro biological activity of EGF molecules coupled to a fluorescein-labeled polyamidoamine dendrimer. The conjugate bound and internalized into several EGFR-expressing cell lines in a receptor-specific fashion. The conjugate effectively induced EGFR phosphorylation and acted as a superagonist by stimulating cell growth to a greater degree than free EGF. Concomitant administration of the chemotherapeutic drug methotrexate completely inhibited cell growth to a degree similar to its effect in the absence of the conjugate. Thus, dendrimer-EGF conjugates serve as EGFR superagonists, but this activity can be overcome by chemotherapeutic drugs. The agonist activity of these materials must be taken into consideration when using EGF conjugates for imaging applications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18193839     DOI: 10.1021/bm701185p

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  33 in total

1.  Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting.

Authors:  Ming-Hsin Li; Seok Ki Choi; Thommey P Thomas; Ankur Desai; Kyung-Hoon Lee; Alina Kotlyar; Mark M Banaszak Holl; James R Baker
Journal:  Eur J Med Chem       Date:  2011-11-23       Impact factor: 6.514

Review 2.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

3.  Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery.

Authors:  Quan Yuan; Eunmee Lee; W Andrew Yeudall; Hu Yang
Journal:  Oral Oncol       Date:  2010-08-21       Impact factor: 5.337

Review 4.  Superagonism at G protein-coupled receptors and beyond.

Authors:  R Schrage; A De Min; K Hochheiser; E Kostenis; K Mohr
Journal:  Br J Pharmacol       Date:  2015-10-24       Impact factor: 8.739

5.  Fibroblast growth factor 2 dimer with superagonist in vitro activity improves granulation tissue formation during wound healing.

Authors:  Caitlin G Decker; Yu Wang; Samantha J Paluck; Lu Shen; Joseph A Loo; Alex J Levine; Lloyd S Miller; Heather D Maynard
Journal:  Biomaterials       Date:  2015-12-15       Impact factor: 12.479

Review 6.  Nanoparticulate systems for growth factor delivery.

Authors:  Sufeng Zhang; Hasan Uludağ
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

7.  Targeting and detecting cancer cells using spontaneously formed multifunctional dendrimer-stabilized gold nanoparticles.

Authors:  Xiangyang Shi; Su He Wang; Mary E Van Antwerp; Xisui Chen; James R Baker
Journal:  Analyst       Date:  2009-04-17       Impact factor: 4.616

Review 8.  Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.

Authors:  Srinivas Ramishetti; Leaf Huang
Journal:  Ther Deliv       Date:  2012-12

9.  Dendrimer-based tumor cell targeting of fibroblast growth factor-1.

Authors:  Thommey P Thomas; Rameshwer Shukla; Alina Kotlyar; Jola Kukowska-Latallo; James R Baker
Journal:  Bioorg Med Chem Lett       Date:  2009-12-03       Impact factor: 2.823

10.  Targeting the EGF receptor for ovarian cancer therapy.

Authors:  Reema Zeineldin; Carolyn Y Muller; M Sharon Stack; Laurie G Hudson
Journal:  J Oncol       Date:  2009-12-28       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.